Krystal Biotech Inc Earnings

Krystal Biotech Inc’s revenue jumped 116.26% since last year same period to $91.14Mn in the Q4 2024. On a quarterly growth basis, Krystal Biotech Inc has generated 8.7% jump in its revenue since last 3-months.

Krystal Biotech Inc’s net profit jumped 423.23% since last year same period to $45.48Mn in the Q4 2024. On a quarterly growth basis, Krystal Biotech Inc has generated 67.33% jump in its net profits since last 3-months.

Krystal Biotech Inc’s net profit margin jumped 141.94% since last year same period to 49.9% in the Q4 2024. On a quarterly growth basis, Krystal Biotech Inc has generated 53.93% jump in its net profit margins since last 3-months.

Krystal Biotech Inc’s price-to-earnings ratio after this Q4 2024 earnings stands at 61.08.

Krystal Biotech Inc’s earning per share (EPS) estimates for the current quarter stand at 1.85 - a 105.79% jump from last quarter’s estimates.

Krystal Biotech Inc’s earning per share (EPS) estimates for the current year stand at 1.85.

Krystal Biotech Inc’s earning per share (EPS) jumped 410% since last year same period to 1.53 in the Q4 2024. This indicates that the Krystal Biotech Inc has generated 410% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Krystal Biotech Inc’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Krystal Biotech Inc’s return on equity (ROE) stands at 0.1.